KOD
No price yet
Announcements
Nothing here yet
Daily updates
- Kodiak shares surged after positive Phase 3 data for two ophthalmic drugs, with results suggesting potential competition with Regeneron's Eylea. The findings increased expectations for Kodiak's retinal disease portfolio.Oct 4, 2026
- Kodiak Sciences reported positive Phase 3 DAYBREAK wAMD results, with both Zenkuda and tabirafusp-ted meeting non-inferiority primary endpoints versus aflibercept.Sep 28, 2026
- Tarcocimab tedromer is being evaluated in the Phase 3 DAYBREAK trial for retinal diseases with an inflammatory component, with topline data expected in September 2026.Sep 19, 2026
FDA designations
Nothing here yet
News
- Zenkuda and tabirafusp-ted meet the primary endpoints in the pivotal DAYBREAK trial in wet AMD, with Zenkuda showing rapid and sustained efficacy and potential for extended 24-week dosing intervalsSep 28, 2026
- Kodiak Sciences will present topline results on September 28, 2026, from the pivotal Phase 3 DAYBREAK study of Zenkuda and KSI-501 in wet age-related macular degenerationSep 26, 2026
- Kodiak Sciences enrolled the first patients in the global Phase 3 ALTO trial of KSI-501 for diabetic macular edemaAug 11, 2026
- Kodiak Sciences completed enrollment in the first pivotal cohort of the Phase 3 PEAK trial of KSI-101Aug 6, 2026
- Kodiak Sciences announced it will present pipeline updates and KSI-101 clinical data at upcoming scientific conferencesMay 1, 2026